Cells undergo apoptotic programmed cell death in response to various stimuli. The process is required for morphogenesis, tissue homeostasis, and host defense. Certain cytokines such as tumor necrosis factor (TNF) and Fas ligand signal through death domain-containing receptors such as tumor necrosis factor receptor 1 (TNFR1) and Fas. The death domain-containing receptor TRAIL-R1 is the latest member in the TNF family and is expressed in most human tissues such as spleen, peripheral blood leukocytes, small intestine, and thymus. Like its fellow receptors TNFR1, Fas, and death receptor 3 (DR3), TRAIL-R1 mediates apoptosis and NF-kB activation in a variety of cells and tissues. The TRAIL-R1 antibody was employed to determine the key role of the signal recognition particle (SRP) complex in apoptosis triggered by TRAIL-R1 but not TRAIL-R21. Johns Hopkins researchers used the TRAIL-R1 antibody to explore novel treatment approaches – including combined TRAIL gene therapy and radiotherapy- for malignant gliomas2. This approach was found to be specific and safe with fine-tuned control. Jane’s group also used a glioma cell line system to monitor the sensitivity of tumor cells to TRAIL with and without bortezomib, and the TRAIL-R1 antibody demonstrated bortezomib sensitizes cells to TRAIL-induced apoptosis in an NFkB-mediated fashion3.
In other cancer types, TRAIL plays a role in downstream signaling of flexible heteroarotinoids (Flex-Het) as evidenced by Lin’s work in lung cancer cells4. Lin employed the TRAIL-R1 antibody to more clearly define the sequence of TRAIL and CAAT/enhancer-binding protein homologous protein (CHOP) in response to these atypical retinoids. Some interesting results in breast cancer therapeutics suggest that the natural compound curcumin enhances TRAIL-induced apoptosis, and the TRAIL-R1 antibody enabled those researchers to elegantly show synergistic effects on downstream pathways such as ERK and Akt 5.
Novus Biologicals offers TRAIL-R1 reagents for your research needs including:
PMIDs